2026 Q2 Portfolio Activity
In 2026 Q2, Cormorant Asset Management, LP maintained a portfolio of 59 distinct positions. The most significant new addition was PARABILIS MEDICINES INC, now representing 6.47% of the total fund value. They heavily accumulated shares in ADLAI NORTYE LTD, increasing the position by 37.3%. The fund also reduced its exposure to PRAXIS PRECISION MEDICINES I by 27.7%.
Position History
hover any row below to update
Loading…
Total Positions
59
Quarter
2026 Q2
Top Holding
PRAX (11.0%)
Top 10 Concentration
59.2%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 59
Cormorant Asset Management, LP Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 10.98% | 14.33% |
#1
Prev: #1
|
6.0 |
—
|
-245,500 | -27.7% |
P
S
|
640,000 | $214,265,600 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BBOT
BRIDGEBIO ONCOL...
|
Healthcare | 6.98% | 8.04% |
#2
Prev: #2
|
5.3 |
—
|
no change | no change |
P
S
|
17,878,594 | $136,234,886 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PBLS
PARABILIS MEDIC...
|
Healthcare | 6.47% | — |
#3
Prev: #—
|
7.1 |
—
|
4,615,612 | — |
NEW
|
4,615,612 | $126,329,300 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
RAPP
RAPPORT THERAPE...
|
Healthcare | 5.67% | 4.65% |
#4
2
Prev: #6
|
3.3 |
—
|
-300,000 | -10.1% |
P
S
|
2,657,521 | $110,738,900 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ERAS
ERASCA INC
|
Healthcare | 5.63% | 4.71% |
#5
Prev: #5
|
3.3 |
—
|
200,000 | 3.4% |
P
S
|
6,000,000 | $109,920,000 | 2021 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
EWTX
EDGEWISE THERAP...
|
Healthcare | 5.23% | 5.16% |
#6
2
Prev: #4
|
2.1 |
—
|
-750,000 | -23.0% |
P
S
|
2,510,000 | $101,981,300 | 2021 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
EYPT
EYEPOINT INC
|
Healthcare | 5.13% | 5.35% |
#7
4
Prev: #3
|
2.6 |
—
|
-1,265,000 | -15.3% |
P
S
|
7,000,000 | $100,100,000 | 2023 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ALMS
ALUMIS INC
|
Healthcare | 4.74% | 4.37% |
#8
1
Prev: #7
|
2.4 |
—
|
-663,645 | -16.8% |
P
S
|
3,285,596 | $92,456,671 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ABVX
ABIVAX SA
|
Healthcare | 4.61% | 4.25% |
#9
1
Prev: #8
|
2.3 |
—
|
-85,000 | -11.2% |
P
S
|
675,000 | $89,950,500 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 3.75% | 4.00% |
#10
Prev: #10
|
1.5 |
—
|
-200,000 | -21.1% |
P
S
|
750,000 | $73,110,000 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DRUG
BRIGHT MINDS BI...
|
Healthcare | 3.24% | 3.88% |
#11
Prev: #11
|
1.8 |
—
|
-159,331 | -15.0% |
P
S
|
900,000 | $63,180,000 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
MLTX
MOONLAKE IMMUNO...
|
Healthcare | 3.20% | 4.19% |
#12
3
Prev: #9
|
1.3 |
—
|
-1,275,000 | -28.5% |
P
S
|
3,205,433 | $62,409,781 | 2022 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BIOA
BIOAGE LABS INC
|
Healthcare | 3.00% | 2.54% |
#13
1
Prev: #14
|
1.7 |
—
|
-500,000 | -17.3% |
P
S
|
2,390,605 | $58,593,729 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 2.60% | 1.31% |
#14
8
Prev: #22
|
2.0 |
—
|
no change | no change |
P
S
|
533,340 | $50,757,968 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ANL
ADLAI NORTYE LT...
|
Healthcare | 2.34% | 1.01% |
#15
13
Prev: #28
|
3.4 |
—
|
1,080,372 | 37.3% |
P
S
|
3,978,229 | $45,749,634 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 2.10% | 3.17% |
#16
4
Prev: #12
|
0.8 |
—
|
-300,000 | -35.3% |
P
S
|
550,000 | $40,964,000 | 2019 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 2.08% | 1.50% |
#17
3
Prev: #20
|
1.3 |
—
|
-125,000 | -8.8% |
P
S
|
1,300,000 | $40,638,000 | 2021 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BHVN
BIOHAVEN LTD
|
Healthcare | 1.99% | 0.75% |
#18
13
Prev: #31
|
3.3 |
—
|
850,000 | 48.3% |
P
S
|
2,610,000 | $38,836,800 | 2017 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
AGMB
AGOMAB THERAPEU...
|
Healthcare | 1.64% | 1.30% |
#19
4
Prev: #23
|
1.7 |
—
|
no change | no change |
P
S
|
2,465,348 | $32,000,217 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
MBX
MBX BIOSCIENCES...
|
Healthcare | 1.56% | 1.68% |
#20
3
Prev: #17
|
0.6 |
—
|
-570,000 | -50.9% |
P
S
|
550,000 | $30,360,000 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CLYM
CLIMB BIO INC
|
Healthcare | 1.41% | — |
#21
Prev: #—
|
4.1 |
—
|
2,106,000 | — |
NEW
|
2,106,000 | $27,462,240 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
OLMA
OLEMA PHARMACEU...
|
Healthcare | 1.38% | 2.92% |
#22
9
Prev: #13
|
0.6 |
—
|
-1,750,000 | -44.9% |
P
S
|
2,150,000 | $26,896,500 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GLTO
DAMORA THERAPEU...
|
Healthcare | 1.33% | 1.98% |
#23
7
Prev: #16
|
0.5 |
—
|
-525,000 | -34.4% |
P
S
|
1,000,000 | $26,010,000 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 1.33% | 1.42% |
#24
3
Prev: #21
|
0.5 |
—
|
-250,000 | -25.0% |
P
S
|
750,000 | $25,935,000 | 2021 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CRBP
CORBUS PHARMACE...
|
Healthcare | 1.13% | 1.11% |
#25
Prev: #25
|
1.5 |
—
|
no change | no change |
P
S
|
2,344,971 | $21,995,828 | 2016 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 1.02% | — |
#26
Prev: #—
|
3.9 |
—
|
225,000 | — |
NEW
|
225,000 | $19,975,500 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DFTX
DEFINIUM THERAP...
|
Healthcare | 0.96% | — |
#27
Prev: #—
|
3.9 |
—
|
400,000 | — |
NEW
|
400,000 | $18,816,000 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
NAMS
NEWAMSTERDAM PH...
|
Healthcare | 0.87% | 1.53% |
#28
9
Prev: #19
|
0.3 |
—
|
-450,000 | -47.4% |
P
S
|
500,000 | $16,945,000 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ROIV
ROIVANT SCIENCE...
|
Healthcare | 0.86% | 1.04% |
#29
2
Prev: #27
|
0.3 |
—
|
-275,000 | -36.7% |
P
S
|
475,000 | $16,810,250 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CABA
CABALETTA BIO I...
|
Healthcare | 0.80% | 0.74% |
#30
2
Prev: #32
|
0.8 |
—
|
-500,000 | -9.1% |
P
S
|
5,000,000 | $15,550,000 | 2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
HELIX ACQUISITI...
|
|
Unknown | 0.71% | 0.66% |
#31
2
Prev: #33
|
1.3 |
—
|
no change | no change |
P
S
|
1,297,500 | $13,805,400 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
ASND
ASCENDIS PHARMA...
|
Healthcare | 0.68% | 1.09% |
#32
6
Prev: #26
|
0.3 |
—
|
-45,000 | -47.4% |
P
S
|
50,000 | $13,336,000 | 2015 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
KLRA
KAILERA THERAPE...
|
Healthcare | 0.62% | — |
#33
Prev: #—
|
3.7 |
—
|
550,000 | — |
NEW
|
550,000 | $12,116,500 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
INSM
INSMED INC
|
Healthcare | 0.41% | 1.56% |
#34
16
Prev: #18
|
0.2 |
—
|
-115,000 | -60.5% |
P
S
|
75,000 | $7,996,500 | 2020 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SNSE
FAETH THERAPEUT...
|
Healthcare | 0.39% | 0.48% |
#35
Prev: #35
|
3.2 |
—
|
722,020 | 235.8% |
P
S
|
1,028,242 | $7,655,550 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 0.39% | — |
#36
Prev: #—
|
3.7 |
—
|
150,000 | — |
NEW
|
150,000 | $7,612,500 | 2023 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TARS
TARSUS PHARMACE...
|
Healthcare | 0.32% | 0.79% |
#37
7
Prev: #30
|
0.1 |
—
|
-125,000 | -55.6% |
P
S
|
100,000 | $6,294,000 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IBIO
IBIO INC
|
Healthcare | 0.32% | — |
#38
Prev: #—
|
3.6 |
—
|
3,570,000 | — |
NEW
|
3,570,000 | $6,247,500 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CRNX
CRINETICS PHARM...
|
Healthcare | 0.24% | 0.46% |
#39
3
Prev: #36
|
0.1 |
—
|
-125,000 | -50.0% |
P
S
|
125,000 | $4,677,500 | 2023 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ARQT
ARCUTIS BIOTHER...
|
Healthcare | 0.24% | 0.53% |
#40
6
Prev: #34
|
0.1 |
—
|
-275,000 | -61.1% |
P
S
|
175,000 | $4,588,500 | 2022 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ARWR
ARROWHEAD PHARM...
|
Healthcare | 0.21% | 0.31% |
#41
2
Prev: #43
|
0.1 |
—
|
-50,000 | -50.0% |
P
S
|
50,000 | $4,075,500 | 2013 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 0.21% | 0.42% |
#42
3
Prev: #39
|
0.1 |
—
|
-100,000 | -57.1% |
P
S
|
75,000 | $4,025,250 | 2023 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
RESEARCH ALLIAN...
|
|
Unknown | 0.20% | — |
#43
Prev: #—
|
3.6 |
—
|
370,000 | — |
NEW
|
370,000 | $3,959,000 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 0.20% | 0.39% |
#44
4
Prev: #40
|
0.1 |
—
|
-100,000 | -50.0% |
P
S
|
100,000 | $3,870,000 | 2022 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ALT
ALTIMMUNE INC
|
Healthcare | 0.19% | — |
#45
Prev: #—
|
3.6 |
—
|
1,250,000 | — |
NEW
|
1,250,000 | $3,800,000 | 2022 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
AMLX
AMYLYX PHARMACE...
|
Healthcare | 0.18% | 0.24% |
#46
1
Prev: #45
|
0.1 |
—
|
-150,000 | -42.9% |
P
S
|
200,000 | $3,592,000 | 2022 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ODTX
ODYSSEY THERAPE...
|
Healthcare | 0.17% | — |
#47
Prev: #—
|
3.6 |
—
|
175,000 | — |
NEW
|
175,000 | $3,274,250 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 0.15% | 0.29% |
#48
4
Prev: #44
|
0.1 |
—
|
-50,000 | -50.0% |
P
S
|
50,000 | $2,906,500 | 2022 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BOLD
BOUNDLESS BIO I...
|
Healthcare | 0.13% | — |
#49
Prev: #—
|
3.6 |
—
|
1,000,000 | — |
NEW
|
1,000,000 | $2,500,000 | 2016 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
QUINCE THERAPEU...
|
|
Unknown | 0.01% | — |
#50
Prev: #—
|
3.5 |
—
|
5,498 | — |
NEW
|
5,498 | $100,009 | — | 13F Filing | 2026-06-30 | 2026-08-14 |
Showing 1-50 of 59 holdings